| 2026-01-07 | +97.0% | news | Yahoo Finance | Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain - Yahoo Finance |
| 2026-01-08 | +48.6% | news | Seeking Alpha | Century Therapeutics gains on $135M private placement |
| 2026-01-08 | +48.6% | legal | SEC EDGAR | IPSC 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2026-01-08 | +48.6% | news | Seeking Alpha | Century Therapeutics gains on $135M private placement - Seeking Alpha |
| 2026-01-08 | +48.6% | news | Stock Titan | Big bet on type 1 diabetes: $135M backs potentially curative cell therapy - Stock Titan |
| 2026-01-08 | +48.6% | legal | Investing News Network | Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes - Investing News Network |
| 2026-01-08 | +48.6% | legal | Investing.com | Century Therapeutics secures $135 million in private placement - Investing.com |
| 2026-01-08 | +48.6% | expansion | TradingView | Century Therapeutics Signs Multiple Financing Agreements - TradingView |
| 2026-01-08 | +48.6% | news | StocksToTrade | Century Therapeutics Inc. (IPSC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade |
| 2026-01-08 | +48.6% | news | StocksToTrade | Century Therapeutics Inc.: Is an Upswing Approaching? - StocksToTrade |
| 2026-01-08 | +48.6% | legal | marketscreener.com | Century Therapeutics secures oversubscribed $135 million private placement financing to support lead program, CNTY-813 - marketscreener.com |
| 2023-12-06 | +47.1% | news | Seeking Alpha | Century Therapeutics stock gains after IND clearance for lupus candidate |
| 2023-12-06 | +47.1% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2024-03-06 | +23.6% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2023-12-22 | +23.0% | news | BioInformant | Century Therapeutics and FUJIFILM Cellular Dynamics to Commercialize iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases - BioInformant |
| 2025-12-17 | +22.8% | earnings | simplywall.st | There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise - simplywall.st |
| 2023-11-09 | -20.1% | earnings | Seeking Alpha | Century Therapeutics GAAP EPS of -$0.55, revenue of $0.1M |
| 2023-11-09 | -20.1% | executive | Seeking Alpha | Century Therapeutics appoints Brent Pfeiffenberger as Chief Executive Officer |
| 2023-11-09 | -20.1% | legal | SEC EDGAR | IPSC 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-11-09 | -20.1% | news | GlobeNewswire | Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - GlobeNewswire |
| 2026-01-22 | +18.1% | analyst | Yahoo Finance | Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance |
| 2023-03-09 | -15.6% | analyst | TradingView | IPSC Forecast — Price Target — Prediction for 2027 - TradingView |
| 2021-12-16 | +14.8% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2024-06-18 | -14.6% | news | Seeking Alpha | Century Therapeutics files to sell 7.87M shares of common stock for holders |
| 2025-11-13 | -14.5% | earnings | Seeking Alpha | Century Therapeutics GAAP EPS of -$0.40 misses by $0.06, revenue of $0M |
| 2025-11-13 | -14.5% | legal | SEC EDGAR | IPSC 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2025-11-13 | -14.5% | news | Yahoo Finance | Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance |
| 2025-11-13 | -14.5% | news | Stock Titan | Century (NASDAQ: IPSC) unveils CNTY-813 iPSC beta islets; IND-enabling start 2025, IND 2026 - Stock Titan |
| 2026-01-09 | +14.4% | news | RTTNews | Century Therapeutics: Is This Stem Cell Stock Taking Root In 2026? - RTTNews |
| 2022-01-10 | +14.4% | legal | SEC EDGAR | IPSC 8-K: 1.01, 3.02 (SEC Filing) |
| 2022-01-10 | +14.4% | news | GlobeNewswire | Century Therapeutics and Bristol Myers Squibb Enter into a - GlobeNewswire |
| 2025-05-15 | +13.4% | legal | SEC EDGAR | IPSC 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-05-15 | +13.4% | news | Intellectia AI | IPSC Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2026-02-09 | +13.3% | news | Seeking Alpha | Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race |
| 2026-02-09 | +13.3% | news | Seeking Alpha | Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race - Seeking Alpha |
| 2026-03-12 | -12.2% | news | GlobeNewswire | Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates |
| 2026-03-12 | -12.2% | earnings | Seeking Alpha | Century Therapeutics GAAP EPS of -$0.14, revenue of $109.2M |
| 2026-03-12 | -12.2% | legal | SEC EDGAR | IPSC 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-12 | -12.2% | earnings | Quiver Quantitative | CENTURY THERAPEUTICS ($IPSC) Releases Q4 2025 Earnings | IPSC Stock News - Quiver Quantitative |
| 2026-03-12 | -12.2% | news | Yahoo Finance | Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates - Yahoo Finance |
| 2026-03-12 | -12.2% | news | Stock Titan | Biotech tests cell therapy as type 1 diabetes cure, eyes 2027 data - Stock Titan |
| 2021-06-21 | +11.4% | news | Zacks Investment Research | Century Therapeutics (IPSC) - Zacks Investment Research |
| 2021-06-21 | +11.4% | news | Zacks Investment Research | Should I buy Century Therapeutics (IPSC) - Zacks Investment Research |
| 2026-01-23 | +11.1% | legal | SEC EDGAR | IPSC 8-K: 5.07 and 8.01 (SEC Filing) |
| 2026-01-23 | +11.1% | news | AD HOC NEWS | Century Therapeutics Stock: Tiny Cap, Big Volatility – Can IPSC’s Cell Therapy Story Recover? - AD HOC NEWS |
| 2022-05-16 | +10.9% | legal | SEC EDGAR | IPSC 8-K: 2.02 and (SEC Filing) |
| 2023-12-11 | +9.7% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2024-02-01 | -9.2% | news | Seeking Alpha | Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy |
| 2026-01-30 | -8.7% | earnings | Insider Monkey | Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission |
| 2026-01-30 | -8.7% | earnings | Yahoo Finance | Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission - Yahoo Finance |
| 2021-06-19 | +8.6% | earnings | MarketBeat | Century Therapeutics (IPSC) Stock Price, News & Analysis $IPSC - MarketBeat |
| 2021-06-19 | +8.6% | earnings | MarketBeat | Century Therapeutics (IPSC) Earnings Date and Reports 2026 $IPSC - MarketBeat |
| 2025-02-28 | -8.5% | news | Investing.com | Century Therapeutics faces Nasdaq delisting over share price - Investing.com |
| 2021-10-13 | +8.5% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2022-07-01 | +7.7% | legal | SEC EDGAR | IPSC 8-K: 1.01 and (SEC Filing) |
| 2025-12-29 | -7.4% | legal | SEC EDGAR | IPSC 8-K: 5.02 (SEC Filing) |
| 2025-12-29 | -7.4% | news | TipRanks | Top Century Therapeutics Executive Makes Bold New Move in Company Stock - TipRanks |
| 2025-03-19 | -7.3% | earnings | Seeking Alpha | Century Therapeutics GAAP EPS of -$1.61 misses by $0.23, revenue of $6.59M beats by $3.24M |
| 2025-03-19 | -7.3% | legal | SEC EDGAR | IPSC 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-03-19 | -7.3% | news | GlobeNewswire | Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire |
| 2025-03-19 | -7.3% | earnings | qz.com | Century Therapeutics Inc. (IPSC) reports earnings - qz.com |
| 2026-04-01 | -6.6% | news | Cổng thông tin điện tử tỉnh Tây Ninh | IPSC Stock Analysis: Century Therapeutics Inc. 3.1% dip to $2.19 biotech performance review - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2024-11-05 | +6.6% | earnings | Seeking Alpha | Century Therapeutics Non-GAAP EPS of -$0.37 beats by $0.08, revenue of $0.8M beats by $0.25M |
| 2024-11-05 | +6.6% | legal | SEC EDGAR | IPSC 8-K: 2.02, 8.01 (SEC Filing) |
| 2024-07-08 | +6.5% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2025-05-16 | +6.4% | earnings | Seeking Alpha | Century Therapeutics GAAP EPS of $0.89, revenue of $109.16M |
| 2026-01-24 | +6.1% | news | AD HOC NEWS | Century Therapeutics Is Suddenly On Everyone’s Radar – But Is IPSC Stock Really A Game-Changer O - AD HOC NEWS |
| 2023-08-09 | -5.9% | earnings | Seeking Alpha | Century Therapeutics GAAP EPS of -$0.56, revenue of $0.09M |
| 2023-08-09 | -5.9% | legal | SEC EDGAR | IPSC 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-01-13 | -5.8% | legal | SEC EDGAR | IPSC 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-01-09 | -5.7% | legal | SEC EDGAR | IPSC 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-08-14 | +5.7% | earnings | Seeking Alpha | Century Therapeutics GAAP EPS of -$0.38 |
| 2025-08-14 | +5.7% | legal | SEC EDGAR | IPSC 8-K: 2.02, 5.02, 7.01 (SEC Filing) |
| 2025-11-17 | +5.6% | analyst | Investing.com | Century Therapeutics stock downgraded by Leerink Partners on lack of catalysts - Investing.com |
| 2025-11-17 | +5.6% | news | MyChesCo | Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MyChesCo |
| 2022-10-03 | -5.5% | legal | SEC EDGAR | IPSC 8-K: 5.02 (SEC Filing) |
| 2024-01-19 | +5.3% | legal | SEC EDGAR | IPSC 8-K: 5.02 (SEC Filing) |
| 2023-10-03 | -5.2% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2026-04-17 | -5.1% | earnings | MarketBeat | Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 19.3% in March - MarketBeat |
| 2024-09-26 | +5.0% | executive | Seeking Alpha | Century Therapeutics taps Morgan Conn as CFO |
| 2024-09-26 | +5.0% | legal | SEC EDGAR | IPSC 8-K: 5.02 (SEC Filing) |
| 2026-02-25 | +4.9% | news | GlobeNewswire | Century Therapeutics to Participate in Upcoming Investor Conferences in March |
| 2026-02-25 | +4.9% | analyst | Investing.com | TD Cowen initiates Century Therapeutics stock rating at Buy - Investing.com |
| 2025-10-12 | -4.9% | news | Yahoo Finance | We Think Century Therapeutics (NASDAQ:IPSC) Needs To Drive Business Growth Carefully - Yahoo Finance |
| 2023-03-16 | -4.4% | earnings | Seeking Alpha | Century Therapeutics GAAP EPS of -$2.27 beats by $0.05, revenue of $5.2M misses by $1.76M |
| 2023-03-16 | -4.4% | legal | SEC EDGAR | IPSC 8-K: 2.02 and (SEC Filing) |
| 2023-07-06 | -4.3% | news | Seeking Alpha | CDXS, RDWR and CDZI are among after hour movers |
| 2023-05-04 | -4.3% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Century Therapeutics (IPSC) - Zacks Investment Research |
| 2022-04-13 | +4.3% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2026-03-20 | -4.1% | legal | Stock Titan | IPSC SEC Filings - Century Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2026-04-21 | +4.1% | earnings | MarketBeat | Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat |
| 2025-07-10 | -4.1% | news | Seeking Alpha | Century Therapeutics files $200M mixed shelf offering |
| 2022-01-13 | -4.1% | legal | SEC EDGAR | IPSC 8-K: 1.01 (SEC Filing) |
| 2024-04-11 | +4.1% | legal | SEC EDGAR | IPSC 8-K: 2.01, 3.02, 7.01 (SEC Filing) |
| 2024-04-11 | +4.1% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2024-04-11 | +4.1% | news | GlobeNewswire | Century Therapeutics Strengthens Position in Autoimmune - GlobeNewswire |
| 2024-03-14 | +4.1% | earnings | Seeking Alpha | Century Therapeutics GAAP EPS of -$2.30, revenue of $2.2M |
| 2024-03-14 | +4.1% | legal | SEC EDGAR | IPSC 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-05-11 | -4.1% | earnings | Seeking Alpha | Century Therapeutics GAAP EPS of -$0.53, revenue of $1.72M |
| 2023-05-11 | -4.1% | legal | SEC EDGAR | IPSC 8-K: 2.02 and (SEC Filing) |
| 2022-03-17 | -3.8% | legal | SEC EDGAR | IPSC 8-K: 2.02 and (SEC Filing) |
| 2022-03-17 | -3.8% | news | citybiz | Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates - citybiz |
| 2023-03-29 | -3.8% | news | Seeking Alpha | Century Therapeutics (IPSC) Investor Presentation - Slideshow |
| 2022-08-25 | -3.7% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2024-05-05 | +3.6% | M&A | BioInformant | Century Therapeutics Raises $60 Million, Acquires Clade Therapeutics, and Expands Pipeline of Allogeneic, iPSC-Derived Cellular Therapies - BioInformant |
| 2023-01-06 | -3.5% | news | InvestorPlace | CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC - InvestorPlace |
| 2026-03-16 | -3.4% | news | Stock Titan | Century Therapeutics (IPSC) SVP sells 7,043 shares to cover tax withholding - Stock Titan |
| 2024-08-08 | -3.3% | earnings | Seeking Alpha | Century Therapeutics GAAP EPS of -$0.38, revenue of $0.8M |
| 2024-08-08 | -3.3% | legal | SEC EDGAR | IPSC 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-12-09 | +3.3% | legal | SEC EDGAR | IPSC 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-12-09 | +3.3% | news | Yahoo Finance | Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors - Yahoo Finance |
| 2025-12-09 | +3.3% | executive | Investing.com | Century Therapeutics appoints two new board members - Investing.com |
| 2025-12-09 | +3.3% | executive | Stock Titan | Century Therapeutics (NASDAQ: IPSC) appoints Dr. Han Lee, Dr. Martin Murphy to board - Stock Titan |
| 2026-03-13 | -3.2% | earnings | Seeking Alpha | Small-Cap healthcare stocks ranked by quant ratings after earnings season |
| 2026-03-13 | -3.2% | news | Investing.com | Leerink reiterates Market Perform on Century Therapeutics stock - Investing.com |
| 2026-03-13 | -3.2% | executive | Stock Titan | Century Therapeutics (IPSC) CEO has 55,397 shares withheld for RSU taxes - Stock Titan |
| 2026-03-13 | -3.2% | earnings | simplywall.st | Century Therapeutics (IPSC) Swings To US$0.51 EPS Profit Challenging Persistent Loss Narratives - simplywall.st |
| 2022-08-11 | +3.2% | legal | SEC EDGAR | IPSC 8-K: 2.02 and (SEC Filing) |
| 2026-03-21 | -3.1% | analyst | AD HOC NEWS | Century Therapeutics stock faces pressure amid biotech volatility as analysts maintain upside target - AD HOC NEWS |
| 2021-06-23 | -3.1% | news | The Business Journals | Century Therapeutics IPO climbs to more than $242M; stock rises over 30% - The Business Journals |
| 2024-06-20 | -3.0% | news | Seeking Alpha | Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101 |
| 2026-03-14 | +2.8% | analyst | AD HOC NEWS | Century Therapeutics Stock Faces Analyst Downgrade Amid Biotech Volatility (ISIN: US15671W1045) - AD HOC NEWS |
| 2022-11-10 | +2.8% | legal | SEC EDGAR | IPSC 8-K: 2.02 and (SEC Filing) |
| 2023-02-10 | -2.7% | news | Seeking Alpha | Century Therapeutics (IPSC) Investor Presentation - Slideshow |
| 2024-06-03 | +2.5% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2026-04-22 | -2.4% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | IPSC Century Therapeutics Inc. posts narrower Q4 2025 loss than expected, shares gain 6.56 percent in daily trading. - Hot Community Stocks - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-03 | +2.3% | news | Stock Titan | Century Therapeutics (NASDAQ: IPSC) CSO has shares withheld for taxes - Stock Titan |
| 2026-04-03 | +2.3% | news | Cổng thông tin điện tử tỉnh Tây Ninh | IPSC Stock Analysis: Century Therapeutics Inc. biotech dips 2.74% to $2.13 in daily trading - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2023-05-05 | +2.3% | legal | SEC EDGAR | IPSC 8-K: 5.02 and (SEC Filing) |
| 2025-07-07 | +2.2% | legal | SEC EDGAR | IPSC 8-K: 2.05 and 5.02 (SEC Filing) |
| 2023-01-04 | -2.2% | news | TradingView | IPSC Stock Price and Chart — NASDAQ:IPSC - TradingView |
| 2025-11-25 | +2.2% | news | Investing News Network | Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference - Investing News Network |
| 2021-08-12 | +2.2% | legal | SEC EDGAR | IPSC 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-08-12 | +2.2% | earnings | Zacks Investment Research | What date does Century Therapeutics's (IPSC) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2021-08-12 | +2.2% | earnings | MarketBeat | Century Therapeutics (IPSC) Institutional Ownership 2026 $IPSC - MarketBeat |
| 2022-05-10 | -2.1% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2021-11-18 | -1.8% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2024-05-15 | -1.7% | news | Seeking Alpha | Century Therapeutics files to sell 15.87M shares of common stock for holders |
| 2023-04-17 | -1.4% | legal | SEC EDGAR | IPSC 8-K: 5.02 and (SEC Filing) |
| 2021-11-10 | -1.3% | legal | SEC EDGAR | IPSC 8-K: 2.02 and (SEC Filing) |
| 2024-05-09 | +1.2% | earnings | Seeking Alpha | Century Therapeutics GAAP EPS of -$0.45 |
| 2024-05-09 | +1.2% | legal | SEC EDGAR | IPSC 8-K: 2.02 and (SEC Filing) |
| 2025-07-21 | -1.2% | analyst | Yahoo Finance | All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy - Yahoo Finance |
| 2026-04-16 | -1.1% | news | Stock Titan | Century Therapeutics (IPSC) seeks vote to add 150M shares, ratify EY - Stock Titan |
| 2026-03-26 | +1.0% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2026-03-26 | +1.0% | news | Stock Titan | Century Therapeutics (IPSC) files $150M ATM shelf with TD Cowen - Stock Titan |
| 2026-03-26 | +1.0% | news | TipRanks | Century Therapeutics Updates ATM Program to Enhance Liquidity - TipRanks |
| 2023-12-13 | +1.0% | news | BioInformant | Century Therapeutics Progressing CNTY-101, its iPSC-derived CAR NK Cell Candidate, Into a Phase 1 Trial - BioInformant |
| 2023-04-12 | -0.9% | earnings | Seeking Alpha | Century Therapeutics CEO Lalo Flores steps down, Greg Russotti appointed as ad-interim Chief Executive Officer |
| 2024-04-09 | +0.9% | legal | SEC EDGAR | IPSC 8-K: 8.01 and (SEC Filing) |
| 2023-08-28 | -0.8% | news | Seeking Alpha | JP Morgan cuts Century Therapeutics to neutral, cites lengthy data timeline |
| 2025-05-28 | -0.7% | news | Yahoo Finance | Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress - Yahoo Finance |
| 2023-11-14 | -0.6% | legal | SEC EDGAR | IPSC 8-K: 5.02 (SEC Filing) |
| 2026-04-02 | -0.6% | news | Benzinga | 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga |
| 2026-04-02 | -0.6% | news | Benzinga | 12 Health Care Stocks Moving In Thursday's After-Market Session - Bullfrog AI Hldgs (NASDAQ:BFRG), CDT Eq - Benzinga |
| 2021-07-31 | +0.5% | news | marketscreener.com | Century Therapeutics, Inc.: Shareholders Board Members Managers and Company Profile | US15673T1007 - marketscreener.com |
| 2021-10-17 | +0.5% | analyst | Benzinga | Century Therapeutics Analyst Ratings and Price Targets | NASDAQ:IPSC - Benzinga |
| 2026-04-10 | -0.5% | news | Stock Titan | Century Therapeutics (IPSC) awards 88,000 stock options to new director - Stock Titan |
| 2026-04-10 | -0.5% | news | Stock Titan | Century Therapeutics (IPSC) director Martin Patrick Murphy files initial Form 3 - Stock Titan |
| 2023-04-06 | +0.1% | news | CoinCodex | Century Therapeutics, Inc. (IPSC) Stock Forecast & Price Prediction 2026–2030 - CoinCodex |
| 2025-11-30 | -0.1% | news | simplywall.st | We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate - simplywall.st |
| 2026-04-24 | — | news | Seeking Alpha | Century Therapeutics: A Biotech With Interesting Optionality Opportunities |
| 2026-04-24 | — | news | Seeking Alpha | Century Therapeutics: A Biotech With Interesting Optionality Opportunities (NASDAQ:IPSC) - Seeking Alpha |